NCT07374731Recruiting
Identification of Biomarkers of Risk for Pre-neoplastic and Neoplastic Lesions for the Development of Gastric Cancer
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
Investigator propose the implementation of circulating biomarker monitoring, focusing on molecules related to the progression of gastric atrophy and/or associated with gastric cancer. Monitoring these biomarkers will provide gastroenterologists with timely information on individuals at risk and, if values worsen during follow-up, will alert physicians observing these patients to evaluate them. This monitoring will be offered to individuals who contact the IBO (Immunopatologia e Biomarcatori Oncologici) Unit at CRO (Centro di Riferimento Oncologico) in Aviano requesting an assessment of gastric function through pepsinogen and G17 gastrin level testing. Monitoring these biomarkers will provide a dynamic analysis of patients' gastric status, allowing for timely intervention in case of deviations from normal values. This proactive approach is important for the preventive management of gastric diseases, particularly for the diagnosis and monitoring of gastric atrophy and gastric cancer. The IBO unit of the CRO in Aviano, together with the pathological anatomy and clinical units of gastroenterology, medical oncology, and surgery, will play a role in coordinating and implementing this monitoring program, thus contributing to the promotion of gastric health and the prevention of associated diseases.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 192 (estimated)
- First submitted
- 21 Jan 2026
- Start date
- 21 May 2025
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- Centro di Riferimento Oncologico - Aviano
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07374731
What you commit to
- Study type: Observational
- Planned participants: 192
- From 21 May 2025 to the primary completion date, 31 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a coexisting or previous diagnosis of another malignant neoplasm in the last 5 years
Age
- Patients under the age of 18
Other
- Pregnant women
- Patients unable to understand, accept, and sign the consent form for data processing
Who the study is looking for
- Aged over 18;
- Ability to understand, accept, and sign the informed consent form for the study;
- Ability to understand, accept, and sign the consent form for data processing;
- Ability to understand, accept, and sign the consent form for the collection of a serum sample for research purposes;
- Patients who are fasting and have requested a pepsinogen test or gastroscopy, or who have gastric cancer prior to treatment;
- Subjects who are fasting and have suspected pre-neoplastic/neoplastic gastric lesions or who have requested a pepsinogen test and for whom endoscopic examination data are available.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS Coordinator of this site? Confirm its status | Aviano | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.